Fumonisin B2 (Synonyms: FB1) |
カタログ番号GC43709
One-Click Copy Product Info
|
Fusarium moniliforme がさまざまな穀物で産生するマイコトキシンであるフモニシン B2 は、スフィンゴシン N-アシルトランスフェラーゼ (セラミド合成酵素) の強力な阻害剤であり、de novo スフィンゴ脂質生合成を妨害します 。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 116355-84-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin [1]. Fumonisin B2 can induce an increase in the mRNA expression of the p21 gene and a decrease in the mRNA expression of the cyclin D1 gene, thereby altering the cell cycle progression[2]. Fumonisin B2 has been widely used to induce cytotoxicity and DNA fragmentation in turkey peripheral blood lymphocytes [3].
In vitro, Fumonisin B2 treatment for 96 hours significantly inhibited the viability of H4TG, FaO, and MDCK cells, with IC50 values of 2, 5, and 2µg/ml, respectively[4]. Treatment with 40µM Fumonisin B2 for 48 hours significantly inhibited the proliferation of GES-1 cells, increased the level of lactate dehydrogenase, and induced endoplasmic reticulum stress[5]. Treatment with 317.4µM Fumonisin B2 for 24 hours significantly induced cell death in HEK293 cells, promoted production of reactive oxygen species (ROS), and caused mitochondrial membrane depolarization [6].
In vivo, Fumonisin B2 treatment via oral administration at a dose of 1mg/kg/day for 3 days significantly exacerbated the inflammatory response in the atopic dermatitis (AD) mouse model, reduced epidermal water loss, and increased production of pro-inflammatory cytokines[7]. Oral administration of a 0.1mg/kg/day dose of Fumonisin B2 for 10 consecutive days significantly exacerbated the pathological process of psoriasis induced by imiquimod in mice[8].
References:
[1] Frisvad J C, Smedsgaard J, Samson R A, et al. Fumonisin B2 production by Aspergillus niger[J]. Journal of agricultural and food chemistry, 2007, 55(23): 9727-9732.
[2] Bondy G S, Barker M G, Lombaert G A, et al. A comparison of clinical, histopathological and cell-cycle markers in rats receiving the fungal toxins fumonisin B1 or fumonisin B2 by intraperitoneal injection[J]. Food and chemical toxicology, 2000, 38(10): 873-886.
[3] Dombrink-Kurtzman M A. Fumonisin and beauvericin induce apoptosis in turkey peripheral blood lymphocytes[J]. Mycopathologia, 2003, 156(4): 357-364.
[4] Shier W T, Abbas H K, Mirocha C J. Toxicity of the mycotoxins fumonisins B1 and B2 and Alternaria alternata f. sp. lycopersici toxin (AAL) in cultured mammalian cells[J]. Mycopathologia, 1991, 116(2): 97-104.
[5] Yu S, Jia B, Liu N, et al. Evaluation of the individual and combined toxicity of fumonisin mycotoxins in human gastric epithelial cells[J]. International Journal of Molecular Sciences, 2020, 21(16): 5917.
[6] Mohan J, Sheik Abdul N, Nagiah S, et al. Fumonisin B2 induces mitochondrial stress and mitophagy in human embryonic kidney (Hek293) cells—a preliminary study[J]. Toxins, 2022, 14(3): 171.
[7] Ando M, Yamaguchi H, Morimoto A, et al. Chronic oral exposure to low-concentration fumonisin B2 significantly exacerbates the inflammatory responses of allergies in mice via inhibition of IL-10 release by regulatory T cells in gut-associated lymphoid tissue[J]. Archives of Toxicology, 2023, 97(10): 2707-2719.
[8] Ando M, Yamaguchi H, Iwashita N, et al. Oral Exposure to Low Concentration of Fumonisin B2, but Not Fumonisin B1, Significantly Exacerbates the Pathophysiology of Imiquimod-Induced Psoriasis in Mice[J]. International Journal of Molecular Sciences, 2024, 25(14): 7852.
| Cell experiment [1]: | |
Cell lines | HEK293 cells |
Preparation Method | HEK293 cells were cultured in 25cm3 cell culture flasks using Dulbecco’s minimum essential medium (DMEM) supplemented with 2.5mM HEPES, 10% foetal bovine serum, 1% pen-strep-fungizone, and 1% L-glutamine, maintained in a humidified incubator (37°C; 5% CO2) until approximately 80% confluent. 2×104 cells/well were seeded and allowed to adhere overnight in a 96-well plate (37°C, 5% CO2). Thereafter, cells were incubated for 24h with varying concentrations of Fumonisin B2 (0, 1, 5, 10, 50, 100, 250, and 500µM). Control wells contained DMEM only. Cell viability was measured. |
Reaction Conditions | 0, 1, 5, 10, 50, 100, 250, and 500µM; 24h |
Applications | Fumonisin B2 treatment significantly decreased the cell viability of HEK293 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Female BALB/c mice |
Preparation Method | Female BALB/c mice (7 weeks old) were housed in standard cages at room temperature (20-26°C) and humidity (40-60%) under a 12/12h light/dark cycle with ad libitum access to autoclaved chow and water. 5% toluene-2,4-diisocyanate (TDI) dissolved in acetone was topically applied onto the depilated abdominal surface on day 1 through day 3, and re-sensitization with 0.5% acetone was performed 3 weeks after the first sensitization. One week after re-sensitization, 0.5% TDI was applied on both sides of the ear auricle as a challenge. Mice were orally administered vehicle alone. After oral administration of Fumonisin B2 at a dose of 1mg/kg/day for 3 consecutive days, the skin condition of mice was analyzed. |
Dosage form | 1mg/kg/day for 3 days; p.o. |
Applications | Fumonisin B2 treatment considerably exacerbated skin thickness, transepidermal water loss, histological features, and proinflammatory cytokine production in mice. |
References: | |
| Cas No. | 116355-84-1 | SDF | |
| 同義語 | FB1 | ||
| Chemical Name | (2R,2’R)-1,2,3-propanetricarboxylic acid, 1,1’-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl] ester | ||
| Canonical SMILES | C[C@H](N)[C@@H](O)C[C@H](O)CCCCCC[C@H](C)C[C@H](OC(C[C@H](C(O)=O)CC(O)=O)=O)[C@H](OC(C[C@H](C(O)=O)CC(O)=O)=O)[C@H](C)CCCC | ||
| Formula | C34H59NO14 | M.Wt | 705.8 |
| 溶解度 | 10mg/ml in methanol & acetonitrile | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4168 mL | 7.0842 mL | 14.1683 mL |
| 5 mM | 283.4 μL | 1.4168 mL | 2.8337 mL |
| 10 mM | 141.7 μL | 708.4 μL | 1.4168 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)